An observational study in Acute-graft-versus-host Disease, sponsored by Lee Dupuis. Completed at 1 site in Canada. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2021-08-19.
Sponsored by Lee Dupuis · Observational
The specific objectives of this study are:
Primary:
1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and severe aGVHD (grade III and IV)
Secondary:
806 studies on the registry are indexed under Graft vs Host Disease; 138 are open to participants now.
This study's enrollment of 105 is above the median of 94 across 102 observational studies indexed under Graft vs Host Disease.
Browse Graft vs Host Disease studies →This is the only study on the registry with Lee Dupuis as lead sponsor.
Counted across the registry records on this site, refreshed daily.
ALLOGENEIC Hematopoietic stem cell transplant recipients
All patients or guardians will provide informed consent or assent as appropriate. Initial contact will be made by a member of the patient's current care team. Consent will be obtained by a co-investigator or the CTSU personnel.
Exclusion Criteria:
-receipt of voriconazole or posaconazole within 14 days of the first cyclosporine dose or at any time until engraftment
Relationship between CSA area-under-the-curve (AUC) prior to ENGRAFTMENT and severe aGVHD
1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and severe aGVHD (grade III and IV)
Time frame: Weekly for 7 weeks or until engraftment and for 100 days after HSCT
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.